Good News At Last For GSK With Daprodustat, But Safety Scrutiny Awaits
Likely To Dominate US Market If Approved
GSK could gain a first-in-class approval for anemia in chronic kidney disease in the US, but approval and uptake of the HIF inhibitor in non-dialysis patients remain uncertain.
